nutriNTM: NUTRITIONAL ASSESSMENT IN NON-TUBERCULOUS MYCOBACTERIA PULMONARY DISEASE

Sponsor
University of Milano Bicocca (Other)
Overall Status
Recruiting
CT.gov ID
NCT05376280
Collaborator
(none)
120
1
26.3
4.6

Study Details

Study Description

Brief Summary

Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is an emerging condition with heterogeneous manifestations from both the microbiological and the clinical point of view. Diagnostic and therapeutic guidelines are available but there are still unmet patients' and physicians' needs, including the exams to perform in the nutritional evaluation and intervention to improve health-related QoL and to control gastrointestinal side-effects during antimicrobial therapy, particularly in those with low body mass index and history of weight loss.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The aim of the study is to evaluate the nutritional status in patients with non-tuberculous mycobacterial pulmonary disease (NTM-PD) and to provide an initial assessment of the potential impact of the introduction of targeted antibiotic therapy on the nutritional status itself.

    Specifically, the primary objective is the assessment of the proportion of underweight subjects, i.e. with Body Mass Index (BMI) <18.5 kg/m2, to confirm that it is significantly higher than that of the general Italian population.

    Study Design: Multicenter Cohort Pilot Observational Study

    Participation in the study consists of two pneumological visits, as per normal clinical practice, (at the beginning of the study, T1, after 6 months, T3, and at the end of the antimicobacterial antibiotic therapy, T5) in which the collection of past medical history, measurement of oxygen saturation, pulmonary functional tests and 6-minute walking tests will be performed. In addition, nutritional assessments (T2, T4, T6) will be carried out at the same time as the pulmonary visits. Nutritional assessments will include anthropometric measurements, questionnaires on nutritional status and physical activity, performing blood chemistry tests, bioimpedance, dynamometry and gait speed 4 meters, to evaluate body composition and physical performance.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    NUTRITIONAL ASSESSMENT IN NON-TUBERCULOUS MYCOBACTERIA PULMONARY DISEASE: AN EXPLORATORY STUDY
    Actual Study Start Date :
    Apr 20, 2022
    Anticipated Primary Completion Date :
    Apr 30, 2024
    Anticipated Study Completion Date :
    Jun 30, 2024

    Outcome Measures

    Primary Outcome Measures

    1. BMI (body mass index) [baseline (NTM-PD diagnosis)]

      kg/m2

    Secondary Outcome Measures

    1. FFMI (fat free mass index) [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      kg/m2

    2. SMI (skeletal muscle mass index) [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      kg/m2

    3. BFMI (body fat mass index) [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      kg/m2

    4. Hand grip [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      kg/m2

    5. Abdominal circumference [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      cm

    6. Malnutrition Universal Screening Tool (MUST) Screening Tool (MUST) [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      questionnaire score: score 0 = low risk of malnutrition; score 1 = medium risk of malnutrition; score equal or higher than 2 = high risk of malnutrition

    7. Mini Nutritional Assessment (MNA) [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      questionnaire score (maximum score 30): total score > 23.5 = normal nutritional status; total score < 23.5 = inadequate nutritional status

    8. plasma vitamin D [baseline (NTM-PD diagnosis), 6-month follow-up, 12-month follow-up]

      vitamin D level in plasma

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age greater than or equal to 18 years;

    • diagnosis of NTM-PD according to the BTS 2017 guidelines

    Exclusion Criteria:
    • severe renal failure, defined as a GFR (glomerular filtration rate) lower than 30ml / min; NYHA class IV;

    • severe liver failure, defined as Child-Pugh score class C;

    • active solid or haematological neoplasms;

    • having already received (currently or in the prior 6 months) antimicobacterial therapy;

    • severe immunosuppression;

    • inability to walk without help;

    • need for oxygen therapy at rest;

    • participation in other interventional experimental protocols with use of a medicinal product.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 San Gerardo Hospital Monza MB Italy 20900

    Sponsors and Collaborators

    • University of Milano Bicocca

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Paola Faverio, Dr., University of Milano Bicocca
    ClinicalTrials.gov Identifier:
    NCT05376280
    Other Study ID Numbers:
    • nutriNTM
    First Posted:
    May 17, 2022
    Last Update Posted:
    May 17, 2022
    Last Verified:
    May 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Paola Faverio, Dr., University of Milano Bicocca
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 17, 2022